{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35.42","upperLimit":"54.34","value":"44.74"},{"groupId":"OG001","lowerLimit":"40.11","upperLimit":"59.04","value":"49.57"},{"groupId":"OG002","lowerLimit":"19.03","upperLimit":"36.28","value":"27.03"},{"groupId":"OG003","lowerLimit":"37.81","upperLimit":"56.98","value":"47.32"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"115"},{"groupId":"OG002","value":"111"},{"groupId":"OG003","value":"112"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>= 30% decrease in the sum of the longest diameter of target lesions by CT, MRI or CXR. If the only target lesion is a solitary pelvic mass measured by physical exam, which is not radiographically measurable, a 50% increase in longest diameter is required; Overall Response (OR) = CR + PR.","dispersionType":"95% Confidence Interval","groups":[{"description":"Paclitaxel 135 mg/m2 IV over 24 hrs on day 1 Cisplatin 50 mg/m2 IV on day 2 OR Paclitaxel 175 mg/m2 IV over 3 hrs on day 1 Cisplatin 50 mg/m2 IV on day 2 OR Paclitaxel 175 mg/m2 IV over 3 hrs on day 1 Cisplatin 50 mg/m2 IV on day 1 Cycles repeated q21 days to progression/toxicity","id":"OG000","title":"Arm I (Paclitaxel and Cisplatin)"},{"description":"Paclitaxel 135 mg/m2 IV over 24 hrs on day 1 Cisplatin 50 mg/m2 IV on day 2 Bevacizumab 15 mg/kg IV day 2 OR Paclitaxel 175 mg/m2 IV over 3 hrs on day 1 Cisplatin 50 mg/m2 IV on day 2 Bevacizumab 15 mg/kg IV day 2 OR Paclitaxel 175 mg/m2 IV over 3 hrs on day 1 Cisplatin 50 mg/m2 IV on day 1 Bevacizumab 15 mg/kg IV day 1 Cycles repeated q21 days to progression/toxicity","id":"OG001","title":"Arm II (Paclitaxel, Cisplatin, Bevacizumab)"},{"description":"Paclitaxel 175 mg/m2 over 3 hrs on day 1 Topotecan 0.75 mg/m2 over 30 mins days 1-3 Cycles repeated q21 days to progression/toxicity","id":"OG002","title":"Arm III (Topotecan Hydrochloride and Paclitaxel)"},{"description":"Paclitaxel 175 mg/m2 over 3 hrs on day 1 Topotecan 0.75 mg/m2 over 30 mins days 1-3 Bevacizumab 15 mg/kg IV day 1 Cycles repeated q21 days to progression/toxicity","id":"OG003","title":"Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab)"}],"paramType":"NUMBER","populationDescription":"All randomized patients.","reportingStatus":"POSTED","timeFrame":"Every cycle (if assessed by physical exam), every other cycle (if assessed by imaging), after the final cycle, then every 3 months x 2 years, then every 6 months x 3 years up to 5 years.","title":"Tumor Response","type":"PRIMARY","unitOfMeasure":"percentage of participants"}